| 摘要: |
| 目的探讨前列地尔联合特利加压素治疗肝硬化合并难治性肝腹水的临床效果。方法选取2014年2月至2016年3月在我院接受治疗的肝硬化难治性腹水患者96例进行研究,根据随机数字表法分为研究组、对照组各48例,两组均给予基础治疗+前列地尔,研究组同时给予特利加压素治疗,对比两组的治疗效果。结果治疗前,两组患者的门静脉、脾静脉内径及血流速度、血清NO、ET及内毒素水平、腹围、腹水深度、24h尿量差异均无统计学意义,差异无统计学意义(P>0.05);治疗后,研究组的门静脉、脾静脉内径、血清NO、ET、内毒素、腹围、腹水深度均低于对照组,差异有统计学意义(P<0.05),研究组的门静脉、脾静脉血流速度、24h尿量均高于对照组,差异有统计学意义(P<0.05);治疗后,研究组腹水消退Ⅰ级25.00%、Ⅱ级43.75%、Ⅲ级27.08%、无效4.17%,对照组腹水消退Ⅰ级12.50%、Ⅱ级37.50%、Ⅲ级35.52%、无效14.58%,研究组疗效优于对照组,差异有统计学意义(P<0.05)。结论基础治疗+前列地尔+特利加压素治疗肝硬化合并难治性腹水的效果较好,可显著的改善门静脉、脾静脉的内径及血流速度,减少患者的腹水量。 |
| 关键词: 肝硬化 难治性 腹水 前列地尔 特利加压素 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Combined Alprostadiland Terlipressin in Treatment of Cirrhosis Complicated with Refractory Ascites |
|
Wang Hao;Jin Yongqiang
|
|
Fifth Affiliated Hospital of Guangzhou Medical University
|
| Abstract: |
| Objective To investigate the clinical efficacy of combined alprostadil and terlipressin in treatment of cirrhosis complicated with refractory liver ascites.Methods A total of 96 patients with cirrhosis complicated with refractory ascites treated in our hospital from February 2014 to March 2016 were selected and divided into study group and control group of 48 patients according to random number table method. Both groups received basic treatment and alprostadil and the study group was also given terlipressin treatment.Then the difference of curative effect of two groups was compared. Results Before treatment,there were no significant differences in the diameters and the blood flow velocity of portal vein and splenic vein,serum NO,ET and endotoxin levels,abdominal circumference,ascites depth and 24 h urine output between two groups( P > 0. 05). After treatment,the diameter of portal vein and splenic vein,serum NO,ET and endotoxin,abdominal circumference and ascites depth of study group were lower than those of control group,the difference of which was statistically significant( P<0. 05).The blood flow velocity of portal vein and splenic vein and 24 h urine output of study group were significantly higher than those of control group( P< 0. 05). After treatment,the ascites of 25. 00% patients of study group faded to gradeⅠ,43. 75% to grade Ⅱ,27. 08% to grade Ⅲ,and there was no effect of last 4. 17% patients. The ascites of 12. 50% patients of the control group faded to grade Ⅰ,37. 50% to grade Ⅱ,35. 52% to grade Ⅲ and there was no effect of last 14. 58% patients. The efficacy of study group was significantly better than that of control group( P<0. 05).Conclusion Combined basic treatment,prostaglandin and terlipressin is more effective in treating cirrhosis complicated with refractory ascites,which can significantly improve the internal diameter and blood flow velocity of portal vein and splenic vein,and reduce the amount of ascites in patients |
| Key words: cirrhosis refractory ascites alprostadil terlipressin |
